

# Senegal

## HIV Country Profile: 2017


WHO/CDS/HIV/18.50

### Demographic and socioeconomic data

|   |  |
|---|--|
|    | <b>15.9 million</b><br>Total population (2017)<br>UNPOP  |
|    | <b>2 620 US\$</b><br>GNI per capita, PPP (2017)<br>World Bank                                    |
|    | <b>315</b><br>Maternal mortality per<br>100 000 live births<br>(2015)<br>World Health Stat., WHO |
|    | <b>5.51%</b><br>Health expenditure, total (% of GDP) (2016)<br>World Bank                        |
|   | <b>68 years</b><br>Life expectancy at birth (2016)<br>UNPOP                                      |
|  | <b>53 US\$</b><br>Health expenditure per capita (2016)<br>World Bank                             |
|  | <b>5</b><br>Total fertility rate (births per woman) (2015-2020)<br>UNPOP                         |
|  | <b>0.51</b><br>Human Development Index Value (2017)<br>UNPOP                                     |




Estimated ART coverage children and adults



Estimated % of pregnant women living with HIV who received ARVs for PMTCT


### 90-90-90 progress towards 2020 targets




### Health sector cascade

|   | Value  | Percent of 90-90-90 |
|---|--------|---------------------|
| People living with HIV who know their status            | 30 400 | 71%                 |
| Reported number of people living with HIV receiving ART | 23 200 | 54%                 |
| People living with HIV with viral load suppression      | 17 400 | 41%                 |

### Estimated number of people newly infected with HIV



### Estimated number of deaths due to AIDS



## Epidemiological HIV data

Value

|   |        |
|---|--------|
| Estimated number of people living with HIV                | 43 000 |
| Estimated number of children aged 0 to 14 living with HIV | 5 000  |
| Estimated number of women (15+) living with HIV           | 25 000 |
| Estimated adult (15-49) prevalence                        | 0.4%   |
| Estimated number of deaths due to HIV                     | 2 100  |
| Estimated number of people newly infected with HIV        | 1 600  |
| Estimated incidence rate per 1000 uninfected population   | <0.1   |

## Antiretroviral therapy (ART)

|   |        |
|---|--------|
| Reported number of people receiving ART   | 23 200 |
| Estimated ART coverage                    | 54%    |
| Reported number of adults receiving ART   | 22 000 |
| Estimated ART coverage (adults, 15+)      | 58%    |
| Reported number of children receiving ART | 1 200  |
| Estimated ART coverage (children, 0-14)   | 25%    |

| Prevention of mother-to-child transmission (PMTCT)   | Value | Year |
|--|-------|------|
| Reported number of pregnant women living with HIV who received antiretrovirals for PMTCT                               | 1 200 | 2017 |
| Estimated percentage of pregnant women living with HIV who received antiretrovirals for PMTCT* <sup>2</sup>            | 53%   | 2017 |
| Final transmission rate including breastfeeding period* <sup>3</sup>   | 20.4  | 2017 |
| Antenatal care coverage - at least one visit (%)   | 95%   | 2015 |
| Antenatal care coverage - at least four visits (%)   | 47%   | 2014 |
| % of pregnant women with known HIV status  | 81%   | 2015 |
| Antenatal care attendees who were tested for syphilis (%)  | 39%   | 2017 |
| Antenatal care attendees who tested positive for syphilis (%)  | 2.4%  | 2017 |
| Antenatal care attendees who tested positive for syphilis and who received benzathine penicillin IM (%)                | 62%   | 2017 |
| % of infants born to women living with HIV receiving a virological test within two months of birth (EID)* <sup>1</sup> | 23%   | 2017 |


\* Tracing indicators for elimination of mother-to-child transmission. A color scheme (green, orange, red) is used to indicate if the country is on target to meet 2020 targets: <sup>1</sup>90% <sup>2</sup>95% <sup>3</sup>Less than 5

#### Key populations


|   |     |
|---|-----|
| Percentage condom use among sex workers with most recent client | 94% |
| Needles distributed per person who inject drugs per year        | 131 |
| HIV prevalence among men who have sex with men (%)              | 42% |
| HIV prevalence among sex workers (%)                            | 7%  |
| HIV prevalence among people who inject drugs (%)                | 2%  |
| Percentage of people who inject drugs receiving OST             | 57% |

#### Median annual price of ARV drug regimens for adults

### First line



### Second line



### National HIV policies and plans

|   |                                   |   |
|---|-----------------------------------|---|
| Implementation of national policy on HIV self-testing (HIVST) | Policy on HIVST in development    | ● |
| Treatment initiation threshold adults and adolescents         | Treat all regardless of CD4 count | ● |
| Treatment initiation threshold children                       | Treat all, regardless of age      | ● |
| Implementation of treat all adults and adolescents            | Implemented countrywide           | ● |

## National HIV policies and plans

|   |   |   |
|---|---|---|
| Dolutegravir (DTG) as part of 1st line ARVs for adults and adolescents  | TDF/[3TC or FTC]/EFV first line ARVs only | ● |
| Implementation of lifelong ART to pregnant & breastfeeding women        | Implemented countrywide                   | ● |
| Implementation of national policy on viral load monitoring              | Fully implemented                         | ● |
| Completion of HIV services cascades                                     | Data not available                        | ● |
| Adaptation of WHO key population guidelines in national plans           | Partially                                 | ● |
| National M&E plan or strategy for HIV                                   | Data not reported                         | ● |
| Method to de-duplicate key data (i.e. unique identifiers)               | Data not reported                         | ● |
| Nationally representative quality assessment of facility-level ART data | Data not reported                         | ● |

© WHO 2018. Some rights reserved. Licence CC BY-NC-SA 3.0 IGO